Investment case
Adial Pharmaceuticals, Inc.
ADIL · 3 developments mapped · last assessed 2026-09-16
Market Ontology has mapped 3 macro, policy, and market developments to Adial Pharmaceuticals, Inc. since 2026-08-17. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for ADIL yet, so no modelled value is shown. The ADIL valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run ADIL on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Adial Pharmaceuticals, Inc. Amends PIPE and Note Exchange Agreements to Reclassify Warrant Liability
Direct financial restructuring improving balance sheet health and reducing potential future liabilities.
· Moves balance sheet strength, risk of future dilution from warrant exercise
- Open question
Adial Pharmaceuticals, Inc. Follow-On — $32M
Direct capital infusion and potential dilution from share issuance. The financing provides necessary capital for operations and the Azora acquisition, but the structure (private financing, note conversion) suggests potential for significant share count increase.
· Moves future capital requirements, dilution impact on per share metrics, risk of future financing rounds
What changed, by assumption
- 2026-08-17Adial Pharmaceuticals, Inc. Follow-On — $32M
- 2026-09-16Adial Pharmaceuticals, Inc. Amends PIPE and Note Exchange Agreements to Reclassify Warrant Liability
- 2026-08-17Adial Pharmaceuticals Completed Acquisition of Azora Therapeutics
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-09-16 | Share count | Bullish | Automatic conversion of Series A Preferred Stock into 12,930,617 shares of Common Stock following stockholder vote. | 1.00 |
| 2026-09-16 | Net debt | Bearish | Liability-management transactions often reduce gross debt or push maturities out. | 0.70 |
| 2026-09-16 | Interest expense | Bearish | Tender/exchange extends maturity profile and typically lowers near-term interest expense. | 0.70 |
| 2026-08-17 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-08-17 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
| 2026-08-17 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-08-17 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-08-17 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-16 | Adial Pharmaceuticals, Inc. Amends PIPE and Note Exchange Agreements to Reclassify Warrant Liability | Bullish | 1-3m | 0.70 |
| 2026-08-17 | Adial Pharmaceuticals, Inc. Follow-On — $32M | mixed | 1-3m | 0.80 |
| 2026-08-17 | Adial Pharmaceuticals Completed Acquisition of Azora Therapeutics | mixed | 1-5y | 0.70 |